J. Chalmers (Dundee (Angus), United Kingdom), M. Crichton (Dundee (Angus), United Kingdom)
This session is built from abstracts published on the ERS Congress platform from 23 August, in an e-poster pdf format with a 3-minute audio narration. Participants and chairs of the session are invited to access all e-posters from 23 August to 4 September prior to the 1-hour live, online discussion scheduled from September 5-7. Please note that during live discussion there will be NO e-poster/abstract presentations, only discussion.
Role of ivermectin in hospitalized patients with mild to moderate COVID-19.
S. Zubair (karachi, Pakistan), A. Zahid (karachi, Pakistan), T. Shahzad (karachi, Pakistan), A. Zubairi (karachi, Pakistan), J. Ahmed Khan (karachi, Pakistan), M. Irfan (karachi, Pakistan)
|   |
Thymalin as an immunomodulation option in severe COVID-19
S. Lukyanov (Chita (Zabaykalsky Krai), Russian Federation), K. Shapovalov (Chita (Zabaykalsky Krai), Russian Federation), P. Tereshkov (Chita (Zabaykalsky Krai), Russian Federation), Y. Smolyakov (Chita (Zabaykalsky Krai), Russian Federation), A. Vanchikova (Chita (Zabaykalsky Krai), Russian Federation), B. Kuznik (Chita (Zabaykalsky Krai), Russian Federation)
| |
Azithromycin and Hydroxychloroquine in hospitalized patients with confirmed SARS-CoV-2 infection - a randomized placebo-controlled trial (ProPAC-COVID Trial)
P. Sivapalan (Hellerup, Roskilde, Denmark), C. Ulrik (Hvidovre, Denmark), T. Lapperre (Copenhagen, Denmark), R. Bojesen (Slagelse, Denmark), J. Eklöf (Hellerup, Denmark), A. Browatzki (Hillerød, Denmark), J. Wilcke (Hellerup, Denmark), V. Gottlieb (Hellerup, Denmark), K. Håkonsson (Hvidovre, Denmark), C. Tidemandsen (Hvidovre, Denmark), O. Tupper (Hvidovre, Denmark), H. Meteran (Hellerup, Denmark), C. Bergsøe (Hellerup, Denmark), E. Brøndum (Hvidovre, Denmark), U. Bødtger (1) Roskilde 2) Slagelse 3) Odense, Denmark), D. Rasmussen (Slagelse, Denmark), S. Jensen (Hellerup, Denmark), L. Pedersen (Copenhagen, Denmark), A. Jordan (Hellerup, Denmark), H. Priemé (Hellerup, Denmark), C. Søborg (Herlev, Denmark), I. Steffensen (Herlev , Denmark), D. Høgsberg (Hellerup, Denmark), T. Klausen (Herlev, Denmark), M. Frydland (Roskilde, Denmark), P. Lange (Hellerup, Denmark), A. Sverrild (Copenhagen, Denmark), M. Ghanizada (Copenhagen, Denmark), F. Knop (Hellerup, Denmark), T. Biering-Sørensen (Hellerup, Denmark), J. Lundgren (Copenhagen, Denmark), J. Jensen (Hellerup, Denmark)
| |
N-acetylcysteine (NAC) in the complex treatment of COVID-associated pneumonia
V. Gaynitdinova (Moscow, Russian Federation), S. Avdeev (Moscow, Russian Federation), Z. Merzhoeva (Moscow, Russian Federation), G. Nuralieva (Moscow, Russian Federation)
| |
Self-proning in COVID-19 patients on low-flow oxygen therapy. A cluster randomised controlled trial
A. Kharat (Genève, Switzerland), E. Dupuis-Lozeron (Genève, Switzerland), C. Cantero (Genève, Switzerland), C. Marti (Genève, Switzerland), O. Grosgurin (Genève, Switzerland), S. Lolachi (Genève, Switzerland), F. Lador (Genève, Switzerland), J. Plojoux (Genève, Switzerland), J. Janssens (Genève, Switzerland), P. Soccal (Genève, Switzerland), D. Adler (Genève, Switzerland)
| |
Addition of convalescent plasma to systemic corticosteroids in early phase of COVID-19
A. YUKSEL (Ankara, Turkey), C. Ilgar (Ankara, Turkey), A. Agaoglu (Ankara, Turkey), E. Akpinar (Ankara, Turkey)
| |
Corticotherapy in SARS CoV 2 pneumonia. Is it useful?
A. Martinez Mesa (Malaga, Spain), J. Lopez Garcia (Malaga, Spain), E. Sanchez Alvarez (Malaga, Spain), A. Aguilar Alvarez (Malaga, Spain), E. Cabrera Cesar (Malaga, Spain), L. Piñel Jimenez (Malaga, Spain)
| |
A novel ambulatory management pathway for Cobid-19 patients using home oximetry.
S. Sharma (Woking Surrey, United Kingdom), S. Saikia (Woking Surrey, United Kingdom), A. Fawzi (Woking Surrey, United Kingdom), S. Thillainayagam (Woking Surrey, United Kingdom), C. Wade (Woking Surrey, United Kingdom), F. Tibbs (Woking Surrey, United Kingdom), E. Spiers (Woking Surrey, United Kingdom), J. Karaj (Woking Surrey, United Kingdom)
| |
COVID-19: treatment of early chronic COVID syndrome
R. Bontsevich (Belgorod, Russian Federation), Y. Vovk (Belgorod, Russian Federation), L. Solovyova (Belgorod, Russian Federation), R. Bontsevich (Belgorod, Russian Federation)
| |
The frequency of prescribing antimicrobial drugs in the initial therapy of COVID-19 at the outpatient stage
R. Bontsevich (Belgorod, Russian Federation), V. Vinyukov (Belgorod, Russian Federation), T. Subina (Belgorod, Russian Federation), Y. Vovk (Belgorod, Russian Federation), D. Dubonosova (Belgorod, Russian Federation)
| |
Tocilizumab treatment for patients with Covid-19 pneumonia - a single centre observational study
D. Gologanu (Bucuresti, Romania), V. Micu (Bucuresti, Romania), V. Nedelcu (Bucuresti, Romania), I. Ion (Bucuresti, Romania), M. Balea (Bucuresti, Romania)
| |
Practical experience in optimizing Covid-19 therapy in an outpatient setting
R. Bontsevich (Belgorod, Russian Federation), Y. Vovk (Belgorod, Russian Federation), L. Solovyova (Belgorod, Russian Federation), R. Bontsevich (Belgorod, Russian Federation)
| |
UTILITY OF BRONCHOALVEOLAR LAVAGE(BAL) TO DETECT INFECTIOUS COMPLICATIONS IN PATIENTS WITH SEVERE SARS-COV-2 PNEUMONIA
B. Gonzalez Quero (Barakaldo, Spain), L. Serrano Fernández (Barakaldo, Spain), A. Rezola Carasusan (Barakaldo, Spain), M. García Moyano (Barakaldo, Spain), S. Castro Quintas (Barakaldo, Spain), A. Urrutia Gajate (Barakaldo, Spain), L. Ruiz Iturriaga (Barakaldo, Spain), R. Zalacain Jorge (Barakaldo, Spain)
| |
Clinical effectiveness of recommended antibiotics in COVID19 pneumonias; assessing national referral centre guidance
E. Bellou (Athens, Greece), E. Keramida (Athens, Greece), I. Bracka (Athens, Greece), I. Karampinis (Athens, Greece), A. Paraskevas (Athens, Greece), C. Gkriniouk (Athens, Greece), D. Zorpidou (Athens, Greece), P. Demertzis (Athens, Greece), G. Hardavella (Athens, Greece)
| |
Hypovitaminosis D and severity of COVID19 respiratory infection in a respiratory intensive care unit (RICU) in Apulia southern Italian region
P. Pierucci (Bari, Italy), V. Quaranta (Bari, Italy), M. Tummolo (Bari, Italy), A. Portacci (Bari, Italy), V. Di Lecce (Bari, Italy), A. Palumbo (Bari, Italy), P. Intiglietta (Bari, Italy), G. Carpagnano (Bari, Italy)
| |
Convalescent Plasma does not improve in-hospital mortality among low SARS-CoV-2-IgG antibodies in COVID-19 hospitalized patients
M. Restrepo (San Antonio, United States of America), F. Wangmang (San Antonio, United States of America), C. Jose (San Antonio, United States of America), S. Sanchez-Reilly (San Antonio, United States of America), N. Soni (San Antonio, United States of America), A. Anzueto (San Antonio, United States of America)
| |
Lung ultrasound may be a valuable aid in decision making for patients admitted with COVID-19 disease
C. Falster (Odense C, Denmark), N. Jacobsen (Odense C, Denmark), L. Madsen (Odense C, Denmark), L. Rasmussen (Odense C, Denmark), J. Davidsen (Odense C, Denmark), F. Knudtzen (Odense C, Denmark), S. Nielsen (Odense C, Denmark), I. Johansen (Odense C, Denmark), C. Laursen (Odense C, Denmark)
| |
Clinical outcomes and use of 4C mortality scoring in COVID-19 patients treated with Remdesivir in a large UK centre
H. Petty (Manchester, United Kingdom), L. Baines (Manchester, United Kingdom), E. Danielsson-Waters (Manchester, United Kingdom), C. Child (Manchester, United Kingdom), C. Templeton (Manchester, United Kingdom), J. Bright (Manchester, United Kingdom), S. Paterson (Manchester, United Kingdom), S. Brij (Manchester, United Kingdom), T. Gorsuch (Manchester, United Kingdom)
| |
Effectiveness of favipiravir in COVID-19 patients with risk factors for mortality: A real world experience from India.
S. Panchal (Mumbai, India), K. Venugopal (Chennai, India), A. Vora (Mumbai, India), A. Daxini (Mumbai, India), P. Dadhich (Ajmer, India), S. Bhagat (Mumbai, India), S. Patil (Mumbai, India), H. Barkate (Mumbai, India), S. Patil (Mumbai, India)
| |